Table 2.
Proportion of patients who experienced a key clinical end point during the 30 days after a procedure and/or temporary interruption of study medication
The nature of the procedures performed, the duration of the interruptions, and the methods of rate calculation varied among the studies. For example, in the ARISTOTLE trial, >1/3 of procedures were performed without study drug interruption.
* Values are for dabigatran 150 mg BID.
† Only cardiovascular deaths are included.
